Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASH

Video

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

In an interview with CancerNetwork®,Christian Buske, MD, of the University Ulm in Germany, spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for patients with lymphoma moving forward.

Transcription:

I think CAR Ts are really amazing. So, we know they have an already established role in diffuse large B-cell lymphoma (DLBCL), but soon we will have data showing us whether CAR Ts can go into second-line treatment. And here, at this year's ASH, there are already approaches using CAR Ts in first-line DLBCL in high-risk patients who are PET-positive after 2 cycles of standard R-CHOP, have high IPI, and have a certain high-risk molecular profile.

We have very interesting data at ASH, which will show us how efficient CAR Ts are in relapsed mantle cell lymphoma. So, I think CAR T is for sure (interesting) and the second are the bispecific antibodies, targeting CD20 and CD38 that we will hear at ASH. A lot of early data about promising data demonstrating that these bispecific antibodies have a high activity… I would probably say these two things.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content